Nebivololo E Idroclorotiazide Mylan (Hydrochlorothiazide, Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors, decreasing cardiac output and heart rate. It also stimulates nitric‑oxide release, causing vasodilation. This dual action contributes to reduced arterial pressure when used with hydrochlorothiazide.

The appropriate dose is determined by the prescribing clinician based on the patient’s blood‑pressure profile, renal function, and concomitant medications. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Safety in pregnancy and lactation has not been fully established. The product should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nebivololo E Idroclorotiazide offers the combined benefits of a cardio‑selective β1‑blocker and a thiazide diuretic in a single tablet, potentially simplifying regimens compared with separate agents. It may be preferred when both heart‑rate control and diuretic action are desired, whereas other classes such as ACE inhibitors or ARBs work via different mechanisms.

Store the tablets at room temperature, below 25 °C, in the original packaging. Protect them from moisture, excessive heat, and direct sunlight to maintain product stability.

The medication is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe hypotension, significant electrolyte disturbances (especially low potassium), acute kidney injury, bradycardia, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience fainting, rapid heartbeat, severe dizziness, or signs of an allergic response.

Patients with known hypersensitivity to nebivolol, hydrochlorothiazide, or any component of the formulation should avoid this product. It is also contraindicated in individuals with severe bradycardia, uncontrolled heart failure, or significant electrolyte imbalances unless corrected under medical supervision.